Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmsc 5.25% Regulatory News (AG99)

Share Price Information for Glaxosmsc 5.25% (AG99)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.925
Bid: 104.15
Ask: 107.50
Change: 0.00 (0.00%)
Spread: 3.35 (3.217%)
Open: 105.925
High: 0.00
Low: 0.00
Prev. Close: 105.925
AG99 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of a Prospectus

4 Aug 2020 18:30

RNS Number : 1383V
GlaxoSmithKline Capital PLC
04 August 2020
 

Publication of Base Prospectus

 

The following base prospectus dated 4th August 2020 has been approved by the Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 

Enquiries:

UK Media enquiries:

Mary Hinks-Edwards

David Mawdsley

Simon Steel

+44 (0) 20 8047 5502

+44 (0) 20 8047 5564

+44 (0) 20 8047 3763

European Analyst/Investor enquiries:

James Dodwell

Danielle Smith

+44 (0) 20 8047 2406

+44 (0) 20 8047 0932

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDIBRGDICDGDGGS
12
Date   Source Headline
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
19th Sep 20233:01 pmRNSEMTN Programme issue - publication of Final Terms
8th Aug 20231:05 pmRNSPublication of Base Prospectus
31st Jul 20234:57 pmRNSHalf-year Report
28th Apr 20235:09 pmRNSAnnual Financial Report
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
9th Sep 20229:11 amRNSPublication of Base Prospectus
2nd Aug 202212:51 pmRNSHalf-year Report
29th Apr 20221:00 pmRNSAnnual Financial Report
14th Apr 20222:30 pmRNSNotice of Optional Redemption
8th Dec 20211:35 pmRNSPublication of a Prospectus
29th Jul 202110:23 amRNSHalf-year Report
11th May 202111:30 amRNSEMTN Prospectus
22nd Apr 202111:21 amRNSAnnual Financial Report
26th Nov 202012:38 pmRNSEMTN Supplementary Prospectus
28th Sep 20203:40 pmRNSNotice of Optional Redemption
4th Aug 20206:30 pmRNSPublication of a Prospectus
31st Jul 20202:02 pmRNSReplacement: Half-year Report
29th Jul 20205:01 pmRNSHalf-year Report
7th May 20205:43 pmRNSPublication of Final Terms
5th May 20208:06 amRNSStabilisation Notice
4th May 202010:41 amRNSStabilisation Notice
30th Apr 20206:09 pmRNSAnnual Financial Report
30th Apr 20205:51 pmRNSPublication of a Prospectus
13th Mar 20205:32 pmRNSEMTN Prospectus Supplement Update
16th Oct 20199:43 amRNSPost Stabilisation Notice - GlaxoSmithKline
19th Sep 20193:37 pmRNSEMTN Programme Issuance of Bonds
16th Sep 20198:31 amRNSPre Stabilisation Notice - GlaxoSmithKline Capital
2nd Aug 20195:34 pmRNSPublication of Base Prospectus
24th Jul 20195:30 pmRNSGlaxoSmithKline Capital plc Half Yearly Report
26th Apr 201911:04 amRNSFinal Results
2nd Aug 20185:07 pmRNSPublication of Base Prospectus
26th Jul 20182:19 pmRNSHalf-year Report
17th May 20184:10 pmRNSPublication of Final Terms
11th May 201812:33 pmRNSPublication of Supplementary Prospectus
12th Apr 20183:01 pmRNSAnnual Financial Report
8th Sep 20174:39 pmRNSPublication of Final Terms
5th Sep 201710:19 amRNSStabilisation Notice
28th Jul 20174:45 pmRNSHalf-year Report
27th Apr 20174:26 pmRNSAnnual Financial Report
4th Aug 20163:50 pmRNSPublication of a Prospectus
27th Jul 20163:52 pmRNSHalf-year Report
26th Apr 20164:09 pmRNSAnnual Financial Report
4th Aug 20152:34 pmRNSPublication of Prospectus
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.